…= 53, 76%), acute lymphoblastic leukaemia (ALL, n = 6, 9%), and multiple myeloma (MM, n = 6, 9%). CAR-T products: axicabtagene ciloleucel (n = 3…
multiple myeloma
This disease is selected. Its supporting articles are shown below.
Articles mentioning multiple myeloma
44 articles · page 3 of 4…rence to oral antineoplastic therapy in patients diagnosed with chronic lymphocytic leukaemia, chronic myeloid leukaemia, or multiple myeloma.Material and Me…
…er, the impact of antibiotic-induced dysbiosis in patients with multiple myeloma (MM) treated with bispecific antibodies (BsAbs) remains unexplo…
…, unlike what happens with CART19 in lymphoblastic leukemia and non-Hodgkin's lymphoma, a high proportion of patients will relapse after CAR-T BCMA th…
…Background Multiple myeloma (MM) is a hematologic malignancy characterized by a high relaps…
…The WHO categorises plasma cell tumours into two primary types: multiple myeloma and plasmacytoma. Plasmacytoma is further classified into solit…
…nd 55.68%, respectively), and among primary cancers, those with breast cancer, multiple myeloma, and lung cancer reported the highest prevale…
…eucaemia, lymphoma, myelodysplastic syndrome, aplastic anaemia, multiple myeloma or recipient of HSCT. The study will involve eight hospitals in…
…y Drug [IMiD], and anti-CD38 monoclonal antibody [mAb]) exposed multiple myeloma (MM), have a poor prognosis, with limited therapeutic options. …
… (CAR) T-cells is a new standard of care in relapsed/refractory multiple myeloma (RRMM). However, long-term data have currently remained sparse.…
…munoproteasome activity. Cell-based assays were performed using multiple myeloma (MM), cutaneous lymphoma and melanoma cells and the lead compou…
…Background Multiple myeloma (MM) is the second most prevalent hematological malignancy and …